newsfilter
← Latest News
GlobeNewswire·

Annovis to Attend the CTAD 2026 with Three Presentations

MALVERN, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy,